About EOCI

EOCI has a demonstrated track record of over 13 years in the CME industry. Our reputation is a result of business integrity and professional agility, as well as resourcefulness and creativity.

In addition to the 25 to 30 CME programs we develop annually, EOCI produces other high-calibre specialist-focused annual congresses in Mont-Tremblant, and Montreal:

Diabetes Update 2017

The 2017 conference is now over. Sign-up the receive information about next year's edition!


Learning Objectives

DAY 1

Following this program, participants will be able to:

  • Assess the sufficiency of the recent cardiovascular outcome clinical trials in diabetes management
  • Interpret the effects of GLP-1 receptor agonists on glycemic targets, hypoglycemia, cardiovascular outcomes, body weight and inflammation
  • Consider the efficacy and safety of SGLT2 inhibitors, their metabolic effects, and possible mechanisms for the observed CV benefits
  • Discuss the available therapies for inflammation as a secondary prevention strategy in atherosclerosis and diabetes
  • Review the use of antiplatelet agents in patients with diabetes and why efficacy may differ in patients with and without diabetes
  • Participate in interactive workshops focusing on the diabetic foot, drug interactions, practical tips for T1DM and exercise in T1DM

DAY 2

Following this program, participants will be able to:

  • Utilize strategies for optimal assessment and management of cardiometabolic risk in diabetic patients
  • Implement appropriate glucose monitoring and adjustment in hospitalized diabetic patients
  • Consider potential mechanisms and prevention strategies for beta cell failure
  • Optimize targets beyond A1c that are relevant to people living with diabetes, including glycemic variability, weight control, quality of life and hypoglycemia
  • Integrate the new evidence on the potential benefits and limitations of insulin pump treatment in T1DM
  • Participate in interactive workshops focusing on the diabetic foot, drug interactions, practical tips for T1DM and exercise in T1DM

DAY 3

Following this program, participants will be able to:

  • Compare the latest evidence on optimal blood pressure targets (intensive vs. standard) for patients with and without diabetes
  • Explain the clinical evidence on new non-statin drugs for lipid lowering in high-risk patients, including potential effects on glycemia
  • Identify recent improvements in glucose monitoring technology and determine the most appropriate glucose monitoring device for each patient
  • Apply data on the pharmacologic effects of new insulins in clinical practice
  • Consider the pros and cons of exercise and extreme exercise in diabetes, including the effects on hypoglycemia and cardiac events